2. Fermandes NC, Perez M. Treatment of pemphigus vulgaris and pemphigus foliaceus: experience with 71 patients over a 20 year period. Rev Inst Med Trop, 2001; 43(1): 33-36.
3. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006; 116:1159.
4. Tsuruta D, Ishii N, Hamada T, et al. IgA pemphigus. Clin Dermatol 2011; 29:437.
5. Amagai M. Pemphigus. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV, et al.. (Eds), Elsevier, 2012. Vol 1, p.461.
6. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159:2010.
7. Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 2009; 145:529.
8. Kljuic A, Bazzi H, Sundberg JP, et al. Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris. Cell 2003; 113:249.
9. Funakoshi T, Lunardon L, Ellebrecht CT, et al. Enrichment of total serum IgG4 in patients with pemphigus. Br J Dermatol 2012; 167:1245.
10. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42:422.
11. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9:844.
12. Bastuji-Garin S, Souissi R, Blum L, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol 1995; 104:302.
13. Abrèu-Velez AM, Hashimoto T, Bollag WB, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol 2003; 49:599.
14. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57:622.
15. Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol 2012; 26:855.
16. Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2012.
Jameel Akhthar Mikrani
Lumbini Medical college
Lumbini Medical College
Lumbini Medical College
How to Cite
Clinical Study of Pemphigus in Lumbini Medical College
Vol 1 No 2 (2013)
Submitted: Jul 5, 2016
Published: Dec 30, 2013
Background: Pemphigus is a worldwide disease and varies in its clinical profile and epidemiology in different regions of the world. The disease is rare and few epidemiological data are available. Objective: The purpose of this study was to evaluate the epidemiologic, clinical, and therapeutic features of pemphigus in Lumbini Medical College. Methods: We retrospectively investigated a total of 70 patients with pemphigus. The parameters including age at diagnosis, sex, diagnostic methods and treatment outcome of the disease. Results: The mean age at the onset was 41.3 years. The male-to-female ratio was 1.18:1. Most of the patients were cured at the end of the treatment. Rest were clinically improved. Conclusion: Pemphigus vulgaris (PV) is the most common clinical subtype in our centre. The disease is more frequent in the fifth decade of life and has a male predominance in our region.